REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 3 filers reported holding REATA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $13,380,721 | +113.4% | 131,235 | +90.3% | 0.01% | +66.7% |
| Q1 2023 | $6,271,025 | +45.6% | 68,973 | -39.1% | 0.00% | +50.0% |
| Q4 2022 | $4,305,749 | +391.0% | 113,339 | +224.8% | 0.00% | – |
| Q3 2022 | $877,000 | -17.3% | 34,900 | 0.0% | 0.00% | – |
| Q2 2022 | $1,061,000 | -5.0% | 34,900 | +2.3% | 0.00% | – |
| Q1 2022 | $1,117,000 | +24.5% | 34,100 | +0.3% | 0.00% | – |
| Q4 2021 | $897,000 | -73.9% | 34,000 | -0.6% | 0.00% | -100.0% |
| Q3 2021 | $3,441,000 | -28.9% | 34,200 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $4,840,000 | +423.8% | 34,200 | +269.0% | 0.00% | – |
| Q1 2021 | $924,000 | -37.4% | 9,269 | -22.4% | 0.00% | -100.0% |
| Q4 2020 | $1,477,000 | +25.8% | 11,950 | -0.8% | 0.00% | 0.0% |
| Q3 2020 | $1,174,000 | -34.0% | 12,050 | +5.7% | 0.00% | 0.0% |
| Q2 2020 | $1,779,000 | -73.3% | 11,400 | -75.3% | 0.00% | -80.0% |
| Q1 2020 | $6,673,000 | -28.8% | 46,230 | +0.9% | 0.01% | 0.0% |
| Q4 2019 | $9,369,000 | +352.4% | 45,830 | +77.6% | 0.01% | +400.0% |
| Q3 2019 | $2,071,000 | -14.9% | 25,800 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $2,434,000 | +8.3% | 25,800 | -1.9% | 0.00% | +100.0% |
| Q1 2019 | $2,248,000 | +70.6% | 26,300 | +11.9% | 0.00% | 0.0% |
| Q4 2018 | $1,318,000 | -31.7% | 23,500 | -0.4% | 0.00% | 0.0% |
| Q3 2018 | $1,930,000 | +208.3% | 23,600 | +31.8% | 0.00% | – |
| Q2 2018 | $626,000 | +89.7% | 17,900 | +11.2% | 0.00% | – |
| Q1 2018 | $330,000 | -17.9% | 16,100 | +13.4% | 0.00% | – |
| Q4 2017 | $402,000 | -9.0% | 14,200 | 0.0% | 0.00% | – |
| Q3 2017 | $442,000 | -1.6% | 14,200 | 0.0% | 0.00% | – |
| Q2 2017 | $449,000 | +80.3% | 14,200 | +29.1% | 0.00% | – |
| Q1 2017 | $249,000 | +3.8% | 11,000 | 0.0% | 0.00% | – |
| Q4 2016 | $240,000 | -17.2% | 11,000 | 0.0% | 0.00% | – |
| Q3 2016 | $290,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |